As of March 31, 2025, cash and marketable securities were $113 million as compared to $127 million as of December 31, 2024, providing the Company with an anticipated cash runway into 2027. During the first three months of 2025, $13 million of net cash was used in operating activities
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics presents data on efficacy of CTX-471
- Compass Therapeutics’ Tovecimig Shows Promise in BTC Treatment, Supporting Buy Rating
- Compass Therapeutics announces first patient dosed in IST evaluating tovecimig
- Biotech Alert: Searches spiking for these stocks today
- Compass Therapeutics price target raised to $24 from $10 at H.C. Wainwright